Ignite Creation Date:
2024-05-06 @ 7:45 PM
Last Modification Date:
2024-10-26 @ 3:13 PM
Study NCT ID:
NCT06123754
Status:
RECRUITING
Last Update Posted:
2024-01-31
First Post:
2023-10-25
Brief Title:
Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC
Sponsor:
3D Medicines Sichuan Co Ltd
Organization:
3D Medicines
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-11-17
Start Date Type:
ACTUAL
Primary Completion Date:
2025-12-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2027-09-30
Completion Date Type:
ESTIMATED
First Submit Date:
2023-10-25
First Submit QC Date:
November 3 2023
Study First Post Date:
2023-11-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-01-30
Last Update Post Date:
2024-01-31
Last Update Post Date Type:
ACTUAL